Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of human group A streptococcal pharyngeal infection

Group A streptococcal (GAS) pharyngitis and the subsequent bacterial colonization of the human throat elicit an immune response that may precipitate acute rheumatic fever in a susceptible host. To study the bacterial determinants that influence throat colonization and induction of humoral immunity, we characterized the behavior of GAS strains in a baboon model. An M‐type 3 clinical isolate of GAS typical of strains that cause pharyngitis and invasive infection was recovered from the pharynx of six out of six baboons for at least 6 weeks after oral inoculation. By contrast, an isogenic mutant deficient in M protein failed to colonize most animals or was rapidly cleared. An isogenic mutant deficient in hyaluronic acid capsule colonized five out of six animals, but only persisted in the pharynx for 14–21 days. Colonized animals developed serum anti‐ streptolysin O (SLO) and anti‐M protein immunoglobulin (Ig)G. The kinetics of the antibody responses were similar to those seen after human infection. Peak titres increased with the duration of throat carriage. Colonization with GAS prevented recurrent colonization after challenge with the homologous wild‐type strain, but not after challenge with a strain of different M protein type. Early clearance of the M protein‐deficient strain was associated with increased susceptibility of this strain to phagocytic killing in non‐immune serum, whereas clearance of the acapsular strain was associated with increased susceptibility to phagocytic killing in the presence of specific antibody. These studies support critical and distinct effects of the GAS M protein and capsule on throat colonization and induction of humoral immunity in a model that reproduces important features of pharyngeal colonization and immune response following human infection.

[1]  M. Wessels,et al.  Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. , 1998, The Journal of clinical investigation.

[2]  E. Tuomanen,et al.  Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bidirectional pathway. , 1998, The Journal of clinical investigation.

[3]  M. Wessels,et al.  Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. , 1998, The Journal of clinical investigation.

[4]  S. Hollingshead,et al.  Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia , 1997, Infection and immunity.

[5]  M. Wessels,et al.  Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus , 1997, Infection and immunity.

[6]  J. Rheinwald,et al.  Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. , 1996, The Journal of clinical investigation.

[7]  M. Wessels,et al.  Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Okada,et al.  M protein and protein F act as important determinants of cell-specific tropism of Streptococcus pyogenes in skin tissue. , 1994, The Journal of clinical investigation.

[9]  M. Markowitz,et al.  Rheumatic Heart Disease in Developing Countries: The Consequence of Inadequate Prevention , 1994, Annals of Internal Medicine.

[10]  L. G. Veasy,et al.  Persistence of acute rheumatic fever in the intermountain area of the United States. , 1994, The Journal of pediatrics.

[11]  S. Michalek,et al.  Role of M protein in pharyngeal colonization by group A streptococci in rats , 1993, Infection and immunity.

[12]  E. Maguin,et al.  An M protein with a single C repeat prevents phagocytosis of Streptococcus pyogenes: use of a temperature‐sensitive shuttle vector to deliver homologous sequences to the chromosome of S. pyogenes , 1993, Molecular microbiology.

[13]  I. Ofek,et al.  Multiple adhesins of streptococci , 1992, Infection and immunity.

[14]  J. Goldberg,et al.  Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Ho,et al.  Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. , 1989, Journal of immunology.

[16]  C. Feidt,et al.  Acute rheumatic fever in western Pennsylvania and the tristate area. , 1987, Pediatrics.

[17]  P. Cleary,et al.  In vivo Streptococcus pyogenes C5a peptidase activity: analysis using transposon- and nitrosoguanidine-induced mutants. , 1987, The Journal of infectious diseases.

[18]  L. G. Veasy,et al.  Resurgence of acute rheumatic fever in the intermountain area of the United States. , 1987, The New England journal of medicine.

[19]  M. Cunningham,et al.  Myosin: a link between streptococci and heart. , 1985, Science.

[20]  E. Baráth,et al.  Fundamentals of Biostatistics. , 1992 .

[21]  R. Kessler,et al.  Growth characteristics of group A streptococci in a new chemically defined medium , 1980, Infection and immunity.

[22]  Angray S. Kang,et al.  Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen , 1977, The Journal of experimental medicine.

[23]  R. Zimmerman,et al.  Human streptococcal disease syndrome compared with observations in chimpanzees. II. Immunologic responses to induced pharyngitis and the effect of treatment. , 1970, The Journal of infectious diseases.

[24]  J. Zabriskie,et al.  Heart-reactive antibody associated with rheumatic fever: characterization and diagnostic significance. , 1970, Clinical and experimental immunology.

[25]  J. Uhr,et al.  Experimental streptococcal infections in baboons. , 1969, Transplantation proceedings.

[26]  A. Berger FUNDAMENTALS OF BIOSTATISTICS , 1969 .

[27]  M. H. Kaplan,et al.  IMMUNOLOGIC RELATION OF STREPTOCOCCAL AND TISSUE ANTIGENS. III. PRESENCE IN HUMAN SERA OF STREPTOCOCCAL ANTIBODY CROSS-REACTIVE WITH HEART TISSUE. ASSOCIATION WITH STREPTOCOCCAL INFECTION, RHEUMATIC FEVER, AND GLOMERULONEPHRITIS. , 1964 .

[28]  R. Lancefield Current knowledge of type-specific M antigens of group A streptococci. , 1962, Journal of immunology.

[29]  G. Stollerman,et al.  Controlled Studies of Streptococcal Pharyngitis in a Pediatric Population: Behavior of the Type-Specific Immune Response , 1961 .

[30]  P. Vanace,et al.  EXPERIMENTAL STREPTOCOCCAL INFECTION IN THE RHESUS MONKEY * , 1960, Annals of the New York Academy of Sciences.

[31]  R. Lancefield PERSISTENCE OF TYPE-SPECIFIC ANTIBODIES IN MAN FOLLOWING INFECTION WITH GROUP A STREPTOCOCCI , 1959, The Journal of experimental medicine.

[32]  C. Rammelkamp,et al.  Prevention of rheumatic fever by treatment of streptococcal infections. II. Factors responsible for failures. , 1958, The New England journal of medicine.

[33]  R. Lancefield DIFFERENTIATION OF GROUP A STREPTOCOCCI WITH A COMMON R ANTIGEN INTO THREE SEROLOGICAL TYPES, WITH SPECIAL REFERENCE TO THE BACTERICIDAL TEST , 1957, The Journal of experimental medicine.

[34]  F. W. Denny,et al.  Type-specific streptococcal antibody. , 1957, The Journal of clinical investigation.

[35]  G. Stollerman,et al.  Relationship of immune response to group A streptococci to the course of acute, chronic and recurrent rheumatic fever. , 1956, The American journal of medicine.

[36]  A. J. Morris,et al.  The role of the streptococcus in the pathogenesis of rheumatic fever. , 1954, The American journal of medicine.

[37]  F. W. Denny,et al.  Studies on immunity to streptococcal infections in man. , 1953, A.M.A. American journal of diseases of children.

[38]  G. Daikos,et al.  Streptococcal Bacteriostatic Antibody in Patients Treated with Penicillin.∗ , 1951, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[39]  F. W. Denny,et al.  Prevention of rheumatic fever; treatment of the preceding streptococcic infection. , 1950 .

[40]  S. Rothbard,et al.  Bacteriologic and immunologic studies on patients with hemolytic streptococcic infections as related to rheumatic fever. , 1948, Archives of internal medicine.

[41]  S. Rothbard,et al.  TYPE-SPECIFIC PROTECTION AND IMMUNITY FOLLOWING INTRANASAL INOCULATION OF MONKEYS WITH GROUP A HEMOLYTIC STREPTOCOCCI , 1946, The Journal of experimental medicine.

[42]  T. Jones,et al.  Studies of Hemolytic Streptococcal Antibodies in Control Groups, Rheumatic Fever, and Rheumatoid Arthritis. II. The Frequency of Antistreptolysin " O," Anti- fibrinolysin, and Precipitating-Antibody Responses in Scarlet Fever, Hemolytic Streptococcal Infections, and Rheumatic Fever. , 1941 .

[43]  R. Lancefield THE ANTIGENIC COMPLEX OF STREPTOCOCCUS HAEMOLYTICUS : I. DEMONSTRATION OF A TYPE-SPECIFIC SUBSTANCE IN EXTRACTS OF STREPTOCOCCUS HAEMOLYTICUS. , 1927, The Journal of experimental medicine.